

Predictive factors for three-year mortality after discharge in elderly patients: A comparison of those with and without diabetes.

Keywords

diabetes, hospitalization, frailty, older adults, mortality, medical inpatients

Abstract

Introduction

Diabetes mellitus (DM) is associated with increased mortality in hospitalized adults. However, data regarding the impact of DM on long-term mortality after discharge in very old patients is scarce.

Material and methods

This prospective study assessed 3-year post-discharge mortality and its predictive factors in older medical patients, focusing on possible differences between patients with and without DM. Medical history, chronic medication use, clinical and laboratory characteristics, Charlson Comorbidity Index (CCI), 5-Fried Frailty score (FFS), Clinical Frailty Scale (CFS), Barthel index (BI), and Katz Index were recorded on admission.

Results

A sample of 815 older adults (46.0% males) with a median age of 83.0 years (IQR: 77.0–88.0) were included in the study. The three-year mortality rate was 54.9% in patients with DM (n=368) and 60.2% in patients without DM (n=447, $p=0.13$ between groups). In multivariate logistic analysis, nursing home residency, higher CCI, higher CFS, higher FFS, lower BI, the total number of days of hospitalization the past year, and hospital-acquired infections were independently associated with the three-year mortality in both groups. In individuals with DM, lower body mass index (BMI) and elevated urine albumin-to-creatinine ratio (UACR) were identified as additional independent predictors of mortality.

Conclusions

A high post-discharge mortality rate was observed in very old medical patients. DM was not identified as an independent factor of post-discharge mortality. Assessment of frailty and disability in very old patients is important for predicting long-term post-discharge mortality. Additionally, in patients with DM, evaluating BMI and UACR may aid in better prediction of three-year mortality.

Predictive factors for three-year mortality after discharge in elderly patients: A comparison of those with and without diabetes.

Ioanna Papakitsou^{*1}, Andria Papazachariou¹, Petros Ioannou¹, Vironas Malikides¹, Theodosios Filippatos¹

¹Internal Medicine Department, University Hospital of Heraklion, Heraklion, Greece

Author Address

Ioanna Papakitsou

School of Medicine, University of Crete, Heraklion, PC 71003, Greece; Internal Medicine Department, University Hospital of Heraklion, Heraklion, PC 71110; jopapakitsou@gmail.com

Andria Papazachariou

School of Medicine, University of Crete, Heraklion, PC 71003, Greece; Internal Medicine Department, University Hospital of Heraklion, Heraklion, PC 71110; apapazachariou@hotmail.com

Petros Ioannou

School of Medicine, University of Crete, Heraklion, PC 71003, Greece; Internal Medicine Department, University Hospital of Heraklion, Heraklion, PC 71110; p.ioannou@uoc.gr

Vironas Malikides

School of Medicine, University of Crete, Heraklion, PC 71003, Greece; Internal Medicine Department, University Hospital of Heraklion, Heraklion, PC 71110; vironasmalikides@hotmail.com

Theodosios Filippatos

School of Medicine, University of Crete, Heraklion, PC 71003, Greece; Internal Medicine Department, University Hospital of Heraklion, Heraklion, PC 71110; filtheo@uoc.gr

* Corresponding author:

Theodosios D. Filippatos, MD, MSc, PhD

AMS Section Editor

Associate Professor of Internal Medicine

Consultant in Internal Medicine / Diabetologist / Lipidologist

Metabolic Diseases Research Unit, Internal Medicine Laboratory,

School of Medicine, PO Box 2208, University of Crete,

Voutes, Heraklion, 71003, Greece

&

Internal Medicine Department, University Hospital of Heraklion,
Voutes, Heraklion, Crete, 71500, Greece
E-mail: filtheo@uoc.gr

Abstract

Background: Diabetes mellitus (DM) is associated with increased mortality in hospitalized adults. However, data regarding the impact of DM on long-term mortality after discharge in very old patients is scarce.

Aims and methods: This prospective study assessed 3-year post-discharge mortality and its predictive factors in older medical patients, focusing on possible differences between patients with and without DM. Medical history, chronic medication use, clinical and laboratory characteristics, Charlson Comorbidity Index (CCI), 5-Fried Frailty score (FFS), Clinical Frailty Scale (CFS), Barthel index (BI), and Katz Index were recorded on admission.

Results: A sample of 815 older adults (46.0% males) with a median age of 83.0 years (IQR: 77.0–88.0) were included in the study. The three-year mortality rate was 54.9% in patients with DM (n=368) and 60.2% in patients without DM (n=447, p=0.13 between groups). In multivariate logistic analysis, nursing home residency, higher CCI, higher CFS, higher FFS, lower BI, the total number of days of hospitalization the past year, and hospital-acquired infections were independently associated with the three-year mortality in both groups. In individuals with DM, lower body mass index (BMI) and elevated urine albumin-to-creatinine ratio (UACR) were identified as additional independent predictors of mortality.

Conclusion: A high post-discharge mortality rate was observed in very old medical patients. DM was not identified as an independent factor of post-discharge mortality. Assessment of frailty and disability in very old patients is important for predicting

74 long-term post-discharge mortality. Additionally, in patients with DM, evaluating
75 BMI and UACR may aid in better prediction of three-year mortality.

76

77 Keywords: diabetes, mortality, older adults, hospitalization, frailty, medical inpatients

78

79

80

Preprint

81 **Introduction**

82
83 In the last decades, life expectancy has risen steadily in most countries,
84 leading to a growing population (1). Aging involves a gradual decline in vitality,
85 physical strength, cognitive ability, and overall physiological function (2). However,
86 disparities often exist between chronological age and biological age (functional
87 capacity). Although physiological functions generally decline with age, the variation
88 in functional status highlights the need for individualized assessment in clinical
89 practice and aging studies (3).

90 Nearly half of individuals diagnosed with diabetes mellitus (DM) belong to
91 the older population (4). DM imposes a substantial burden on healthcare systems
92 globally, contributing to morbidity and mortality through its numerous complications
93 and associated comorbidities (5, 6). While relative literature lacks data regarding
94 hospital outcomes of or after hospitalization of very old patients with DM, certain
95 studies have shown that patients often experience a decline in functional capacity
96 upon discharge compared to admission (7). Evaluating outcomes and identifying
97 mortality predictors in this population is crucial for optimizing medical care and
98 enhancing healthcare services. Notably, predictors of long-term mortality in older
99 hospitalized adults after discharge -particularly clinical factors such as comorbidities,
100 functional status, laboratory values (e.g., renal function, nutritional markers), and
101 systemic inflammation- remain a topic of considerable interest (8, 9). However,
102 studies with long-term follow-up in the late elderly population admitted to medical
103 departments, particularly in Greek and southern Mediterranean populations, remain
104 limited.

This prospective study aimed to assess three-year post-discharge mortality rate and predictive factors in older medical patients, identifying possible differences between patients with and without DM.

Materials and Methods

This prospective cohort study was conducted in the Internal Medicine Department of the University Hospital of Heraklion, Crete, Greece, with patient recruitment taking place between May 2019 and June 2022. Patients aged ≥ 65 years, as per the World Health Organization's (WHO) definition of older adults, were included in this study (10). Additionally, according to WHO, older patients were classified into two groups; "early elderly," aged between 65 to 74 years, and "late/very elderly," aged over 75 years.

On admission, demographic and somatometric data, past medical history [type 2 DM, heart failure (HF), coronary heart disease (CHD), cerebrovascular disease, peripheral artery disease (PAD), chronic kidney disease (CKD), hypertension, dyslipidemia, dementia, chronic medication use [antidiabetic, antihypertensive, hypolipidemic, diuretics, antiplatelet drugs], causes of hospitalization, laboratory parameters on admission [full blood count, serum creatinine, glycated hemoglobin (HbA1C), albumin levels, urine-albumin to creatinine ratio (UACR)], the duration of hospitalization the past year before current admission and the occurrence of any previous hospitalizations were recorded.

Laboratory analyses were conducted at the Central Laboratory of the University Hospital of Heraklion. HbA1c was measured using high-performance liquid chromatography (HPLC) with the Bio-Rad D-10 analyzer. Serum parameters

including albumin, creatinine, C-reactive protein (CRP) and lipid profile components [total cholesterol and low-density lipoprotein (LDL) cholesterol] were determined using standard enzymatic colorimetric methods. Specifically, CRP was measured via immunoturbidimetric assay, LDL cholesterol and total cholesterol were quantified using the CHO-POD enzymatic method, and serum albumin was measured using the bromocresol green dye-binding method. UACR was calculated from spot urine samples, based on urine albumin measured by the pyrogallol red dye-binding method and creatinine quantified by the kinetic Jaffe reaction.

In addition, cognitive status and dependency on activities of daily living (ADL) were assessed using the Katz index and the Barthel index (BI), respectively. Patients with BI score ≤ 61 were identified as having moderate to total disability (11). Similarly, those with a Katz index score ≤ 3 were identified as having significant disability (12). Frailty was assessed using the 5-Fried Frailty score (FFS) and Clinical Frailty Scale (CFS). A cutoff score of ≥ 6 for CFS was used to identify those with higher than moderate frailty (13). Additionally, a cut-off of ≥ 3 for FFS defined frailty (14). In order to assess morbidity, the Charlson comorbidity index (CCI) was estimated; patients with a CCI index ≥ 5 were classified as having severe morbidity (15). Severity upon admission was also assessed using the qSOFA score. Additionally, outcomes regarding length of hospital stay (LOS), Intensive Care Unit (ICU) transfer, and mortality rates were assessed and evaluated. Discharged patients were followed for three years, with data on readmissions and mortality collected through telephone interviews or, when unavailable, from medical records and hospital administrative systems.

The study received ethical approval by the Ethics Committee of the University Hospital of Heraklion. Informed consent was obtained from all patients participating

in the study. In cases where a patient was unable to provide consent, consent was obtained from their legal representative.

Statistical Analysis

The study population was categorized into two groups: DM-group and non-DM group. Continuous data were analysed using the student test for normally distributed variables and the Mann-Whitney test for non-normally distributed data. Categorical data were analyzed using the Chi-square test when all expected cell counts were ≥ 5 , and Fisher's exact test was applied when expected counts were < 5 . Data are presented as numbers (%) for categorical variables and means [\pm Standard deviation (SD)] or medians [interquartile range (IQR)] for continuous variables. All tests were two-tailed, and a p-value ≤ 0.05 was considered significant.

Logistic regression analysis models were developed in both groups to assess three-year post-discharge mortality predictors. Age, sex, past medical history, previous hospitalizations within the past year, chronic medication use, laboratory exams, frailty, and dependency on activities of daily living scores were the examined parameters. Multivariate logistic regression analyses were employed, including the factors having $p < 0.05$ in the univariate analysis. All the parameters mentioned above were calculated with SPSS version 26.0 (IBM Corp., Armonk, N.Y., USA).

Results

During the study period, 1134 individuals were admitted to the medical ward; of those, $n=34$ were < 65 years old and excluded. Out of 1100 individuals aged ≥ 65 years, 151 were excluded due to scheduled admission or for not providing informed consent, 127 died during hospitalization, and follow-up records were unavailable for seven individuals. Therefore, the working sample for assessing three-year post-

discharge mortality consisted of 815 discharged patients, as outlined in the study's flowchart (Figure 1). Among these patients, n=168 (20.6%) were early elderly, and n=647 (79.4%) were late elderly. In the whole sample, the median age was 83.0 years (IQR 77.0, 88.0), and 375 (46%) were male.

Three hundred sixty-eight (45.2%) individuals had DM with a mean HbA1c level of 6.5 ± 1.6 (**Table 1**). The median duration of DM was 13.0 (11.0, 18.0) years. DM group had a marginally lower median age compared to the non-DM group (82 vs 85 years, $p<0.01$) and a slightly elevated BMI (26.0 vs 25.0, $p<0.01$). The occurrence of any hospitalizations during the year preceding the current admission and the total number of days spent in the hospital during that period were similar between the two groups. The DM group exhibited a numerically greater, but not statistically significant, disability rate based on BI (mean BI score 64 vs. 54, respectively $p=0.09$) and Katz Index (39.1 vs 42.3, $p=0.39$). Regarding frailty, no statistically significant differences were found between those with DM and those without DM as assessed by FFS (33.2% vs. 38.5%, $p=0.12$) and CFS (39.7% vs. 45.2%, $p=0.12$) (**Table 1**).

A significantly greater percentage of individuals with DM exhibited increased morbidity, based on CCI, compared to the non-DM group ($p<0.01$, **Table 1**). Additionally, patients with DM exhibited a significantly higher prevalence of polypharmacy ($p<0.01$) and received in greater percentages ACE inhibitors and statins ($p<0.01$) compared to patients without DM.

Regarding causes of admission, anemia and HF decompensation occurred significantly more frequently in those with DM compared to the rest. Higher qSOFA scores on admission were observed in those with DM ($p<0.01$).

During admission, the DM group experienced higher rates of hospital acquired infections (HAIs) ($p<0.01$). The use of vasoactive drugs was observed in higher rates

in those with DM compared to the rest (6.8% vs. 2.5%, $p<0.01$). However, no statistically significant difference was observed in ICU admission. The mean length of hospital stay (approximately 7 days) was similar in both groups. The overall incidence of three-year post-discharge mortality among the 815 elderly patients was 57.8%. Mortality rates were comparable between the DM and non-DM groups, at 54.9% and 60.2%, respectively (Table 1).

In patients who were discharged no statistically significant differences regarding three-year mortality rates were observed between DM and non-DM groups (χ^2 2.31, $p=0.13$). Linear regression analyses were performed to identify predictors of three-year mortality and to assess any differences between patients with and without DM. The results from univariate and multivariate analyses for the DM group are presented in **Table 2** and for the non-DM group in **Table 3**. Nursing home residency, elevated CCI, higher CFS, higher FFS, lower BI, longer duration in the hospital before admission, and HAIs were identified as statistically significant factors of three-year post-discharge mortality in both groups. In patients with DM, lower BMI ($p=0.03$) and increased UACR ($p=0.04$) during admission were observed as additional significant three-year post-discharge mortality predictors.

Discussion

There is a gap in the literature regarding the late elderly population admitted to medical departments, particularly in Greek and southern Mediterranean populations (16, 17). To the best of our knowledge, our study is one of the few studies examining post-discharge mortality in late elderly subjects and has the longest period of observation. Our results indicate that almost two out of three late elderly patients

discharged from a medical department die in the next three years. This high mortality rate is an observation that should be considered when planning the post-discharge plan and regimen of this population which includes older, frail individuals with a greater burden of comorbidities. Despite the higher rate of comorbidities, no statistically significant difference in three-year mortality was observed between patients with and without DM. This is a key finding of this study, indicating that DM in this age group, the very old patients, is not independently associated with long-term post-discharge mortality. The post-discharge mortality predictors that were identified in both groups included higher CCI, longer duration of past hospitalization, higher CFS, lower BI, higher FFS, HAIs, and nursing home residency. In the DM group, lower BMI and higher UACR levels were additionally identified as three-year post-discharge mortality predictors.

Our results align with other studies on elderly hospitalized patients with DM, indicating that DM did not significantly impact mortality (18-21). In the RepoSI trial, which analyzed data from internal medicine and geriatric wards, diabetes was not a predictor of 1-year mortality (18). This study contributes to the existing literature by providing long-term mortality data and a direct comparison between groups with DM and non-DM groups. Our cohort findings in a population with high frailty, advanced age, and diabetes duration over 10 years revealed high overall mortality, with DM status not being a critical factor, possibly reflecting advances in DM management and chronic disease care.

Frailty, as measured by the CFS and FFS, emerged as highly significant predictors for long-term mortality in both groups in this study. Previous research has demonstrated that CFS is a strong predictor of mortality in hospitalized patients (22-24). Similarly, BI was also found to be a predictor of mortality in older patients (25). Frailty reflects

overall vulnerability, and disability reflects the loss of functional capacity. Both factors, as indicated in our study, contribute to mortality risk in late elderly hospitalized patients regardless of the presence of DM. Therefore, these scores have the potential to provide useful information for the planning of treatment and long-term care of older patients. Moreover, this study confirms the evidence of CCI being a strong independent factor of long-term mortality in very elderly patients (22, 26).

Older patients are particularly vulnerable to HAIs due to age-related immune decline, which heightens their susceptibility to infections (27, 28). This study identified HAIs as factors independently associated with three-year mortality, irrespective of DM. While DM can increase infection risk and severity, frailty appears to play a more critical role in very old patients (29). Frailty in this population often leads to prolonged hospital stays, increased morbidity, and a higher risk of in-hospital mortality, underscoring that age-related vulnerability may outweigh the impact of DM on infection outcomes (30, 31).

There is a gap in the literature regarding the impact of prior hospitalizations on long-term mortality in very elderly patients. This study found that the duration of hospitalization the past year before the current admission was identified as a significant predictor of three-year mortality. More than half of hospitalized older patients experience new functional impairments upon discharge (32). Each hospitalization is often accompanied by the onset of geriatric syndromes, further complicating patient outcomes and diminishing quality of life (33).

Furthermore, residing in a nursing home was another independent mortality predictor for both groups. According to the literature, heightened risks of mortality, recurrent hospitalizations, and post-discharge complications are observed at higher rates in

older individuals living in nursing homes compared to those dwelling in the community (34). In our analysis, more than half of the residents in nursing homes were classified as frail and disabled, according to the CFS and BI, respectively. Nursing homes typically accommodate patients who are in the later stages of life, often with significant comorbidities and severe levels of dependency (34). Consequently, nursing home residency should be considered an indirect indicator of frailty.

A lower BMI has been identified as an independent factor for increased mortality in older individuals with DM (35, 36). Notably, it appears that being overweight or mildly obese may offer protective benefits for older adults (37, 38), leading to the context of the “obesity paradox,” where overweight older individuals may experience better outcomes than their normal-weight or underweight peers (39). BMI does not accurately capture key aspects such as adiposity distribution, muscle mass, or recent weight changes, factors that are particularly relevant in older adults. As such, BMI should be interpreted alongside more comprehensive nutritional and functional indicators when assessing health risks in the elderly. Sarcopenia, is partially associated with the frailty syndrome and is a recognized predictor of adverse outcomes, including increased mortality (40-42). Protein-energy malnutrition, which disproportionately affects hospitalized older adults, is a major modifiable factor driving muscle loss and functional decline (43-45).

Albuminuria is prevalent among the elderly due to the pathophysiological changes associated with aging (46, 47). UACR was independently associated with long-term mortality in adults with type 2 DM aged >65 years old (48). Our study adds to previous results the fact that UACR on admission, despite its possible large variability

due to acute illness, is identified as a predictor of three-year mortality after discharge in very old patients with DM.

In our study population of very old adults with DM, the use of newer antidiabetic agents such as SGLT2 inhibitors and GLP-1 receptor agonists was limited. Although the cardioprotective and renoprotective trials of these drug classes have been established, there is limited data in very elderly populations; thus, these drugs might not have been incorporated into routine practice in geriatric populations during the recruitment period of our study. Additionally, concerns regarding tolerability in late elderly patients, including risk of hypotension, dehydration, or genitourinary infections, may have contributed to the limited use of SGLT2 inhibitors in this very old population (49). Similarly, frailty and risk of unintended weight loss, sarcopenia, or significant gastrointestinal side effects (50) may have restrained GLP-1 agonist use in our sample.

Despite its prospective design and sample size of very old adults, this study has certain limitations. The single-center design of this study may limit the generalizability of its findings to broader populations; however, our hospital admits patients from both urban and rural regions. Moreover, additional scores assessing frailty and nutritional status have been used in the literature, and their incorporation could have further enriched our study results. Acknowledging these limitations is crucial for future research endeavors aimed at better understanding the impact of DM and its comorbidities on health outcomes of very old people.

Conclusion

This study highlights that individuals of very old age have a high three-year post-discharge mortality rate, whereas DM *per se* is not a significant contributor to the long-term mortality. Frailty and comorbidity, prior hospitalizations during the past year and nursing home residency were observed as independent predictors of long-term mortality in our sample. Among subjects with DM, lower BMI and elevated UACR on admission were found as additional three-year post-discharge mortality factors. These findings highlight the need for regular assessment of frailty and disability in very old hospitalized patients, whereas, in those with DM, the assessment of BMI and UACR may aid in better long-term mortality risk estimation.

Disclosure statement

Conflicts of interest/competing interests: The authors assert that they have no competing financial interests or personal relationships that could have potentially influenced the work reported in this paper. Assoc. Professor Filippatos reports participation in advisory boards for Lilly and Astra Zeneca and lecture honoraria from Boehringer Ingelheim, Mylan, Astra Zeneca, Lilly, Recordati, Bausch Health, Servier, Viatris, Omega-Pharma and Innovis, outside of the present work.

Acknowledgments: No acknowledgments

Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethics approval The study was conducted in accordance with the Declaration of Helsinki, and approved by the *Ethics Committee of the University Hospital of Heraklion with protocol number 716/ 16-01-2019*.

Data Availability Statement (DAS): The data that support the findings of this study are not publicly available due to privacy and ethical restrictions but are available from the corresponding author upon reasonable request and with permission from the ethics review board.

Authors' contributions: Conceptualization, I.P. and T.F.; methodology, I.P.; software, I.P.; validation, I.P, A.P, and T.F.; formal analysis, I.P; investigation, I.P, A.P and T.F; resources, I.P; data curation, I.P.; writing—original draft preparation, I.P and A.P; writing—review and editing, I.P and T.F.; visualization, T.F.; supervision, T.F.; All authors have read and agreed to the published version of the manuscript.

366 References

- 367 1. Fadnes LT, Celis-Morales C. Life expectancy can increase by up to 10 years following
368 sustained shifts towards healthier diets in the United Kingdom. *Nat Food*. 2023;4(11):961–
369 968.
- 370 2. Singh S, Bajorek B. Defining 'elderly' in clinical practice guidelines for
371 pharmacotherapy. *Pharm Pract (Granada)*. 2014;12(4):489.
- 372 3. Khan SS, Singer BD, Vaughan DE. Molecular and physiological manifestations and
373 measurement of aging in humans. *Aging Cell*. 2017;16(4):624–633
- 374 4. Bellary S, Kyrou I. Type 2 diabetes mellitus in older adults: clinical considerations and
375 management. *Nat Rev Endocrinol*. 2021;17(9):534–548.
- 376 5. Dal Canto E, Ceriello A, Rydén L, Ferrini M, Hansen TB, Schnell O, et al. Diabetes as a
377 cardiovascular risk factor: an overview of global trends of macro- and microvascular
378 complications. *Eur J Prev Cardiol*. 2019;26(2_suppl):25–32.
- 379 6. Huang ES. Management of diabetes mellitus in older people with comorbidities.
380 *BMJ*. 2016;353:i2200.
- 381 7. Bhatt PP, Sheth MS. Comparison of fatigue and functional status in elderly type 2
382 diabetes patients versus age and gender matched individuals. *Aging Med (Milton)*.
383 2024;7(1):84–89.
- 384 8. Forbes A. Reducing the burden of mortality in older people with diabetes: a review
385 of current research. *Front Endocrinol (Lausanne)*. 2020;11:133.
- 386 9. Hazar A, Gundogus B. Assessment of inflammatory markers, disease severity and
387 comorbidities in very elderly patients with acute respiratory diseases. *Arch Med Sci*.
388 2025;21(2):451–462.
- 389 10. Cybulski M, Krajewska-Kułak E, Sowa P, Orzechowska M, Van Damme-Ostapowicz K,
390 Rozwadowska E, et al. Elderly peoples' perception of young people—a preliminary study.
391 *Iran J Public Health*. 2013;42(10):1099–1105.
- 392 11. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. *Md State Med J*.
393 1965;14:61–65
- 394 12. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged.
395 The index of ADL: a standardized measure of biological and psychosocial function. *JAMA*.
396 1963;185(12):914–919.
- 397 13. Rockwood K, Theou O. Using the Clinical Frailty Scale in allocating scarce health care
398 resources. *Can Geriatr J*. 2020;23(3):210–215.
- 399 14. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in
400 older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci*. 2001;56(3):M146–
401 M156.
- 402 15. Huang YQ, Gou R, Diao YS, Yin QH, Fan WX, Liang YP, et al. Charlson comorbidity
403 index helps predict the risk of mortality for patients with type 2 diabetic nephropathy. *J*
404 *Zhejiang Univ Sci B*. 2014;15(1):58–66.
- 405 16. Beretta MV, Dantas Filho FF, Freiberg RE, Feldman JV, Nery C, Rodrigues TC.
406 Sarcopenia and type 2 diabetes mellitus as predictors of 2-year mortality after hospital
407 discharge in a cohort of hospitalized older adults. *Diabetes Res Clin Pract*. 2020;159:107969.
- 408 17. Koziół M, Towpik I, Żurek M, Niemczynowicz J, Wasążnik M, Sanchak Y, et al.
409 Predictors of rehospitalization and mortality in diabetes-related hospital admissions. *J Clin*
410 *Med*. 2021;10(24):
- 411 18. Argano C, Natoli G, Mularo S, Nobili A, Lo Monaco M, Mannucci PM, et al. Impact of
412 diabetes mellitus and its comorbidities on elderly patients hospitalized in internal medicine
413 wards: data from the RePoSi registry. *Healthcare (Basel)*. 2022 Jan 3;10(1):86
- 414 19. Corrao S, Nobili A, Natoli G, Mannucci PM, Perticone F, Pietrangelo A, et al.
415 Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients

hospitalized in internal medicine wards: data from the RePoSI Registry. *Acta Diabetol.* 2021;58(9):1225–1236.

20. Smerdely P. Mortality is not increased with diabetes in hospitalised very old adults: a multi-site review. *BMC Geriatr.* 2020;20(1):522
21. Corrao S, Argano C, Natoli G, Nobili A, Corazza GR, Mannucci PM, et al. Disability, and not diabetes, is a strong predictor of mortality in oldest old patients hospitalized with pneumonia. *Eur J Intern Med.* 2018;54:53–59
22. Molina S, Martinez-Urrea A, Malik K, Libori G, Monzon H, Martínez-Camblor P, et al. Medium and long-term prognosis in hospitalised older adults with multimorbidity: a prospective cohort study. *BMJ Open.* 2023;18(6):e0285923.
23. Soh CH, Lim WK, Reijnierse EM, Maier AB. Clinical frailty scale score during geriatric rehabilitation predicts short-term mortality: RESORT cohort study. *Ann Phys Rehabil Med.* 2023;66(1):101645.
24. Church S, Rogers E, Rockwood K, Theou O. A scoping review of the Clinical Frailty Scale. *BMC Geriatr.* 2020;20(1):393.
25. Conde-Martel A, Hemmersbach-Miller M, Marchena-Gomez J, Saavedra-Santana P, Betancor-Leon P. Five-year survival and prognostic factors in a cohort of hospitalized nonagenarians. *Eur J Intern Med.* 2012;23(6):513–518.
26. Tal S. Mortality in the oldest-old adults after discharge from acute geriatric ward. *Gerontol Geriatr Med.* 2023;9:23337214231156300.
27. Elias R, Hartshorn K, Rahma O, Lin N, Snyder-Cappione JE. Aging, immune senescence, and immunotherapy: a comprehensive review. *Semin Oncol.* 2018;45(4):187–200.
28. Tannou T, Koeberle S, Manckoundia P, Aubry R. Multifactorial immunodeficiency in frail elderly patients: contributing factors and management. *Med Mal Infect.* 2019;49(3):167–172.
29. Holt RIG, Cockram CS, Ma RCW. Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment. *Diabet Med.* 2024;67(7):1168–1180.
30. Cristina ML, Spagnolo AM, Giribone L, Demartini A, Sartini M. Epidemiology and prevention of healthcare-associated infections in geriatric patients: a narrative review. *Int J Environ Res Public Health.* 2021;18(10):5333.
31. Jump RL, Crnich CJ, Mody L, Bradley SF, Nicolle LE, Yoshikawa TT. Infectious diseases in older adults of long-term care facilities: update on approach to diagnosis and management. *J Am Geriatr Soc.* 2018;66(4):789–803.
32. Admi H, Shadmi E, Baruch H, Zisberg A. From research to reality: minimizing the effects of hospitalization on older adults. *Rambam Maimonides Med J.* 2015;6(2):e0017.
33. Mudge AM, McRae P, Hubbard RE, Peel NM. Hospital-associated complications of older people: a proposed multicomponent outcome for acute care. *J Am Geriatr Soc.* 2019;67(2):352–356.
34. Boucaud-Maitre D, Letenneur L, Dramé M. Comparison of mortality and hospitalizations of older adults living in residential care facilities versus nursing homes or the community: a systematic review. *BMJ Open.* 2023;18(5):e0286527.
35. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. *Lancet.* 2009;373(9669):1083–1096.
36. Kim YG, Han KD, Roh SY, Jeong JH, Choi YY, Min K, Shim J, Choi JI, Kim YH. Being underweight is associated with increased risk of sudden cardiac death in people with diabetes mellitus. *J Clin Med.* 2023;12(3):1045..
37. Hong JS, Kang HC. Body mass index and all-cause mortality in patients with newly diagnosed type 2 diabetes mellitus in South Korea: a retrospective cohort study. *BMJ Open.* 2022;12(4):e048784.

38. Werner C, Sturm M, Heldmann P, Fleiner T, Bauer JM, Hauer K. Predictors of 2-year post-discharge mortality in hospitalized older patients. *J Clin Med*. 2024;13(5):1352
39. Dramé M, Godaert L. The obesity paradox and mortality in older adults: a systematic review. *Nutrients*. 2023 Apr 6;15(7):1780.
40. Lewandowicz A, Sławiński P, Kądalska E, Targowski T. Some clarifications of terminology may facilitate sarcopenia assessment. *Arch Med Sci*. 2020;16(1):225–232.
41. He Q, Xia W. Analysis of the current status of computed tomography diagnosis of sarcopenia. *Arch Med Sci*. 2025;21(2):374–382
42. Yu Z, Liang K, Chen X, Tang H, Chen X. Association of the triglyceride glucose index with computed tomography-based low muscle mass. *Arch Med Sci*. 2025 May 5. doi:10.5114/aoms/203760.
43. Chan HCN, Fei X, Leung ELY, Langston K, Marshall S, van der Meij BS. Post-discharge consequences of protein-energy malnutrition, sarcopenia, and frailty in older adults admitted to rehabilitation: a systematic review. *Clin Nutr ESPEN*. 2023;54:382–397
44. Constans T, Bacq Y, Bréchet JF, Guilmot JL, Choutet P, Lamisse F. Protein-energy malnutrition in elderly medical patients. *J Am Geriatr Soc*. 1992;40(3):263–268.
45. Wang J, Chen Z, Chen L. Nutritional burden from the global burden of disease. *Arch Med Sci*. 2024;20(4):1077–1088.
46. Barzilay JI, Buzkova P, Shlipak MG, Bansal N, Garimella P, Mukamal KJ. Hospitalization rates in older adults with albuminuria: the Cardiovascular Health Study. *J Gerontol A Biol Sci Med Sci*. 2020;75(12):2426–2433.
47. Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. *Kidney Int*. 2002;61(6):2165–2175.
48. de Boer IH, Katz R, Cao JJ, Fried LF, Kestenbaum B, Mukamal K, et al. Cystatin C, albuminuria, and mortality among older adults with diabetes. *Diabetes Care*. 2009;32(10):1833–1838.
49. Bakker WM, Gansevoort RT. Sodium-glucose cotransporter 2 inhibitors in older patients with CKD. *J Am Soc Nephrol*. 2024;35(10):1446–1449
50. Onoviran OF, Li D, Toombs Smith S, Raji MA. Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. *Ther Adv Chronic Dis*. 2019 Jul 12;10:2040622319862691

508

509

510

511

512


513

514

Preprint

515

516 **Figure 1:** Flow-chart of the study



517

518

519

520

521

522

523

524

525

526

527

529 **Table 1** Baseline characteristics, causes of admission, and outcomes

Characteristics	Total sample (n=815)	DM (n=368, 45.2%)	Non-DM (n=447, 54.8%)	p-value (DM vs. non-DM)
Demographics				
Age, median (IQR)	83 (77, 87)	82 (77, 87)	85 (78, 89)	<0.01
Male, n (%)	375 (46.0)	165 (44.8)	210 (47.0)	0.57
BMI, mean \pmSD	25.7 \pm 4.1	26.3 \pm 4.1	25.1 \pm 4.1	<0.01
CCI, mean \pmSD	5.5 \pm 1.8	6.2 \pm 1.7	5.0 \pm 1.7	<0.01
Charlson Comorbidity severity (≥ 5)	604 (74.1)	315 (85.6)	328 (64.7)	<.0.01
Nursing home residents	68 (8.3)	22 (6.0)	46 (10.3)	0.03
Bed-ridden	322 (39.5)	131 (36.4)	188 (42.1)	0.11
Comorbidities				
Hypertension	610 (74.8)	315 (85.6)	295 (66.0)	<0.01
Dyslipidemia	303 (37.2)	219 (50.9)	120 (23.4)	<0.01
CAD	161 (19.8)	99 (26.9)	62 (13.9)	<0.01
PCI	67 (8.2)	40 (10.9)	27 (6.0)	0.02
CABG	32 (3.9)	17 (4.6)	15 (3.4)	0.37
HF	352(42.9)	201 (54.6)	149 (33.3)	<0.01
Stroke	94 (11.5)	53 (14.4)	41 (9.2)	0.02
CKD	122 (15.0)	75 (20.4)	47 (10.5)	<0.01
Dementia	320 (39.3)	131 (35.6)	189 (42.3)	0.06
Parkinson	78 (9.6)	32 (8.7)	46 (10.3)	0.47
Hyperuricemia	144 (17.7)	83 (22.6)	63 (14.1)	<0.01
Hypothyroidism	139 (17.1)	84 (22.8)	55 (12.3)	<0.01
Functional and				

frailty status				
Katz index, mean \pm SD	3.7 \pm 2.5	3.8 \pm 2.4	3.6 \pm 2.6	0.11
Katz index (disability, ≤ 3)	333 (40.9)	144 (39.1)	189 (42.3)	0.39
Barthel index, mean \pm SD	61.5 \pm 41.7	64.2 \pm 39.8	54.2 \pm 43.1	0.09
Barthel index (disability, < 61)	327 (40.1)	139 (37.8)	188 (42.1)	0.22
FFS, mean \pmSD	2.4 \pm 1.5	2.4 \pm 1.5	2.4 \pm 1.5	0.99
Fried Frailty Scale (frailty, ≥ 3)	294 (36.1)	122 (33.2)	172 (38.5)	0.12
CFS, mean \pmSD	4.9 \pm 2.2	4.8 \pm 2.1	4.9 \pm 2.3	0.36
CFS (frailty ≥ 6)	348 (42.7)	146 (39.7)	202 (45.2)	0.12
Chronic medication use				
Anti-platelets COX inhibitors, n (%)	169 (20.7)	106 (28.8)	63 (14.1)	<0.01
Anti-platelets ADPi, n (%)	87 (10.7)	54 (14.7)	33 (7.4)	<0.01
Thiazide diuretics, n (%)	132 (16.2)	62 (16.8)	70 (15.7)	0.70
Pottasium sparing diuretics, n (%)	101 (12.4)	58 (15.8)	43 (9.6)	0.01
Loop diuretics, n (%)	273 (33.5)	147 (39.9)	126 (28.2)	<0.01
ACEi, n (%)	155 (19.0)	91 (24.7)	64 (14.3)	<0.01
ARBs, n (%)	326 (34.6)	160 (37.2)	166 (32.4)	0.13
SGLT-2i, n (%)	25 (2.7)	25 (5.8)	0	<0.01

GLP-1 analogs, n (%)	10 (1.1)	10 (2.3)	0	<0.01
B-blockers, n (%)	322 (39.5)	184 (50.0)	138 (30.9)	<0.01
CCBs, n (%)	243 (29.8)	145 (39.4)	98 (21.9)	<0.01
Statins, n (%)	287 (35.2)	183 (49.7)	104 (23.3)	<0.01
PPIs, n (%)	359 (44.0)	198 (53.8)	1661 (36.0)	<0.01
Polypharmacy n (%)	602 (73.9)	329 (89.4)	273 (61.1)	<0.01
Causes of admission				
RTI, n (%)	307 (37.7)	123 (33.4)	184 (41.2)	0.02
UTI, n (%)	224 (27.5)	108 (29.3)	116 (26.0)	0.31
SSTI, n (%)	70 (8.6)	38 (10.3)	37 (7.2)	0.13
Acute heart failure decompensation, n (%)	139 (17.1)	75 (20.4)	64 (14.3)	0.03
AKI, n (%)	226 (27.7)	113 (30.7)	113 (25.3)	0.10
Electrolyte disorders, n (%)	153 (18.8)	79 (21.5)	74 (16.6)	0.09
Anemia, n (%)	143 (17.5)	77 (20.9)	66 (14.8)	0.03
Hypoglycemia, n (%)	18 (2.2)	17 (4.6)	1 (0.2)	<0.01
Laboratory values				
Albumin, mean \pm SD	3.3 \pm 0.6	3.2 \pm 0.6	3.3 \pm 0.6	0.37
HbA1C, mean \pm SD	6.5 \pm 1.5	6.5 \pm 1.6	6.5 \pm 1.3	0.54
GFR Cockcroft, mean \pm SD	51.4 \pm 30.5	49.5 \pm 29.1	52.9 \pm 31.5	0.12
LDL cholesterol,	91.8 \pm 40.1	90.0 \pm 38.5	93.3 \pm 41.5	0.27

	mean \pm SD			
UACR , median (IQR)	618.0 (276.0, 1284.0)	628.0 (281.0, 1256.0)	610.0 (269.5, 1301.5)	0.82
CRP , median (IQR)	7.4 (1.8, 14.0)	6.8 (1.7, 14.7)	7.5 (1.9, 13.8)	0.83
qSOFA 3/3 criteria , n (%)	7 (0.9)	1 (0.3)	6 (1.3)	<0.01
Vasoactive need , n (%)	36 (4.4)	25 (6.8)	11 (2.5)	<0.01
Complication-health care-associated infection , n (%)	50 (6.1)	34 (9.2)	16 (3.6)	<0.01
ICU admission , n (%)	9 (1.1)	5 (1.4)	4 (0.9)	0.74
LOS	7.0 (5.0, 14.0)	7.0 (4.0, 14.0)	7.0 (4.0, 13.65)	0.62
Previous hospitalization , n (%)	347 (42.6)	169 (45.9)	179 (39.8)	0.09
Total days hospitalized (in the past year) before current admission , mean \pm SD	0 (0, 7.0)	0 (0, 8.0)	0 (0, 6.0)	0.35
Readmission rates , n (%)	507 (62.2)	228 (62.0)	279 (62.6)	0.89
Three-year post-discharge mortality , n (%)	471 (57.8)	202 (54.9)	269 (60.2)	0.13

530 DM: diabetes, BMI: body mass index, CAD: coronary artery disease, PCI:
531 percutaneous coronary intervention, CABG: coronary artery bypass graft, AF: atrial
532 fibrillation, CKD: chronic kidney disease, CFS: clinical frailty scale, ACEi:
533 angiotensin-converting enzyme inhibitors, CCBs: calcium channel blockers, PPIs:

534 proton pump inhibitors, RTI: respiratory tract infection, UTI: urinary tract infection,
535 SSTI: skin and soft tissue infection LOS: length of hospital stay, ICU: intensive care
536 unit, UACR: urine albumin to creatinine ratio, CCI: Charlson Comorbidity index,
537 FFS: Fried Frailty Score

538

539

540

541

Preprint

542

543 **Table 2:** Univariate and multivariate analyses for predictive factors of three- year
 544 post-discharge mortality in subjects with diabetes (n=368).
 545

	Univariate analysis p-value	Multivariate analysis p-value
Age	<0.01	0.68
BMI	<0.01	0.03
Katz index	<0.01	0.48
CCI	<0.01	0.03
UACR	0.04	0.04
Total days hospitalized (in the past year) before current admission	<0.01	0.05
Barthel index	<0.01	0.04
FFS	<0.01	0.02
CFS	<0.01	0.01
UTI	<0.01	0.66
AKI	0.03	0.60
Dementia	<0.01	0.69
Nursing home residents	<0.01	0.04
Bed-ridden	<0.01	0.10
Statins	<0.01	0.64
Healthcare-associated infection	<0.01	0.03
Previous hospitalization	<0.01	0.29

546 BMI: body mass index, RTI: respiratory tract infection, UTI: urinary tract infection,
 547 LOS: length of hospital stay, AKI: acute Kidney Injury, UACR: urine albumin to
 548 creatinine ratio, CCI: Charlson Comorbidity index, FFS: Fried Frailty Score, CFS:
 549 clinical frailty scale

550

551

Preprint

Table 3: Univariate and multivariate analyses for predictive factors of three-year post-discharge mortality in subjects without diabetes (n=447).

	Univariate analysis p-value	Multivariate analysis p-value
Age	<0.01	0.34
BMI	<0.01	0.70
Katz-index	<0.01	0.32
CCI	<0.01	0.03
Total days hospitalized (in the past year) before current admission	<0.01	<0.01
Barthel index	<0.01	<0.01
FFS	0.02	<0.01
CFS	<0.01	<0.01
Polypharmacy	<0.01	0.44
UTI	<0.01	0.85
AKI	0.02	0.82
Electrolyte disorders	<0.01	0.13
Antibiotics last 3 months	<0.01	0.69
Dementia	<0.01	<0.01
Nursing home residency	<0.01	0.02
Bed-ridden	<0.01	0.73
ACEi	0.04	0.50
statins	<0.01	0.30
Healthcare-associated infection	<0.01	<0.01
Previous hospitalization	<0.01	0.55

555 BMI: body mass index, RTI: respiratory tract infection, UTI: urinary tract infection,
556 LOS: length of hospital stay, AKI: Acute Kidney Injury, UACR: urine albumin to
557 creatinine ratio, CCI: Charlson Comorbidity index, FFS: Fried Frailty Score, CFS:
558 clinical frailty scale, ACEi: angiotensin-converting enzyme inhibitors

559

Preprint

PREDICTIVE FACTORS FOR THREE-YEAR MORTALITY AFTER DISCHARGE IN ELDERLY PATIENTS: A COMPARISON OF THOSE WITH AND WITHOUT DIABETES

